A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110)

导出原文传递

翻译打印收藏纠错

作者： Nishino, Kazumi ^[1] ; Imamura, Fumio ^[2] ; Kumagai, Toru ^[3] ; Katakami, Nobuyuki ^[4] ; Hata, Akito ^[5] ; Okuda, Chiyuki ^[6] ; Urata, Yoshiko ^[7] ; Hattori, Yosihihiro ^[8] ; Tachihara, Motoko ^[9] ; Yokota, Souichirou ; Nishimura, Takashi ; Kaneda, Toshihiko ; Satouchi, Miyako ; Morita, Satoshi ; Negoro, Shunichi

作者单位： Toneyama Natl Hosp, Natl Hosp Org, Dept Thorac Oncol, Toyonaka, Osaka, Japan ^[1] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan ^[2] West Hosp, Kobe City Med Ctr, Dept Resp Med, Kobe, Hyogo, Japan ^[3] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Thorac Oncol, Higashinari Ku, Osaka 5378511, Japan ^[4] Kyoto Katsura Hosp, Dept Resp Med, Kyoto, Japan ^[5] Hyogo Canc Ctr, Dept Thorac Oncol, Akashi, Hyogo, Japan ^[6] Hyogo Canc Ctr, Dept Med Oncol, Akashi, Hyogo, Japan ^[7] Inst Biomed Res & Innovat, Div Integrated Oncol, Chuo Ku, Kobe, Hyogo 6500047, Japan ^[8] Kobe Univ, Grad Sch Med, Dept Resp Med, Kobe, Hyogo 657, Japan ^[9]

关键词 Non-squamous non-small-cell lung cancer Bevacizumab Docetaxel S-1 Second-line Phase II

发布时间 2015-09-17

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交